|
Dual Mechanism of Action
MP8 causes release of cytokine receptors from the cell surface, which bind and inactivate circulating cytokine. MP8 also eliminates the receptor binding sites from the cell membrane, thereby preventing signal transduction from free cytokine.
Multiple Pathway Inhibition
MP8 hinhibits both the TNFα and IL-6 pathways.
Validated Targets/Established Development Path
TNF and IL-6 are well validated targets for treating inflammation, meaning that the development path for MP8 is well established.
Patient Friendly Administration
MP8 will be administered to patients on a weekly or bi-weekly schedule via subcutaneous injection, thus avoiding the need for intravenous infusion.
Low Manufacturing Cost
MP8 is a small single chain polypeptide produced in bacteria, implying significant cost and yield advantages. Glycosylation is not required.
Natural Protein
Unlike Enbrel®, Humira® and Remicade®, MP8 is a naturally occurring protein encoded in the human genome. It should therefore be less immunogenic.
Strong Patent Position
Patents covering MP8 as a composition of matter (recombinant protein, fragments, and homologs), methods of use, and methods of production have been issued in the United States, and are granted or pending in 17 foreign jurisdictions. Patent term including extensions will last through at least 2020.
The patents also claim the discovery and testing of new agents that cause cytokine receptor shedding.
|